An authority from the NSW Ministry of Health is required to prescribe or supply dexamfetamine, lisdexamfetamine (Vyvanse®), or methylphenidate (Concerta®, Ritalin®, Ritalin LA®).

A pharmacist in NSW cannot dispense a prescription for psychostimulant medication unless the prescription bears an authority number issued by the NSW Ministry of Health, regardless of which state or territory a prescription is issued in.

Note: An authority issued to a prescriber by the NSW Ministry of Health is separate to the authority required from Medicare Australia for a patient to receive a PBS subsidised medicine.

Completed forms and supporting documentation should be faxed to Monitoring and Compliance section, Pharmaceutical Regulatory Unit on (02) 9424 5889.

On this page

Prescribe psychostimulant for a child

Specialists (e.g. paediatricians, child and adolescent psychiatrists) and other designated prescribers may apply for authorisation to prescribe psychostimulant medication for the treatment of ADHD in a person aged under 18 years by submitting an PDF Application for Authority to Prescribe a Psychostimulant for ADHD in a Child or Adolescent.

Submit an PDF Application for Authority to Prescribe a Psychostimulant in a High Dose for the Treatment of ADHD in a Child or Adolescent to prescribe children doses greater than:

  • 1mg/kg daily or 50mg daily of dexamfetamine
  • 2mg/kg daily or 108mg daily of methylphenidate
  • 70mg daily of lisdexamfetamine

To prescribe psychostimulant medication to a person aged under 18 years for all other diagnoses submit an PDF Application for Authority to Prescribe a Schedule 8 Drug – Psychostimulant.

Requirements for the authorisation and prescribing of psychostimulants for the management of ADHD in children are described in PDF Criteria for the Diagnosis and Management of Attention Deficit Hyperactivity Disorder in Children and Adolescents (TG181).

Prescribe psychostimulant for an adult

Specialists (e.g. psychiatrists, neurologists, respiratory & sleep physicians, palliative care physicians) may apply for authorisation to prescribe psychostimulant medication for a person aged 18 years or over by submitting an PDF Application for Authority to Prescribe a Schedule 8 Drug – Psychostimulant.

Please contact the Monitoring and Compliance section at Pharmaceutical Regulatory Unit during business hours on (02) 9424 5923 for further information if psychostimulant prescribing is required for a diagnosis other than ADHD, narcolepsy, treatment-resistant depression, or fatigue due to cancer.

Requirements for the authorisation and prescribing of psychostimulants for the management of ADHD in adults are described in PDF Criteria for the Diagnosis and Management of Attention Deficit Hyperactivity Disorder in Adults (TG190).

General practitioners

General practitioners may apply for authorisation to continue to prescribe a psychostimulant for a person aged 18 years or over by submitting an PDF Application for Authority to Prescribe a Schedule 8 Drug – Psychostimulant.

Note: GPs seeking authorisation to prescribe psychostimulant medication for a patient must provide a supporting letter from the patient's current specialist with their application.

A general practitioner may apply for a person aged under 18 years in certain emergency circumstances by submitting an PDF Application for Authority to Prescribe a Psychostimulant for ADHD in a Child or Adolescent.

Apply for general authority number

Specialists (paediatricians, psychiatrists, child and adolescent psychiatrists and neurologists) may apply to the Ministry of Health for a general authority number (CNS number or S28c number) to prescribe psychostimulant medication for the treatment of ADHD by submitting an PDF Application to Prescribe Dexamfetamine, Lisdexamfetamine or Methylphenidate for the Treatment of ADHD under Clause 84 or Clause 84(2)(b).

From August 2018, prescribers who prescribe dexamfetamine, lisdexamfetamine or methylphenidate for persons with ADHD using their CNS or s28c general authority number are no longer required to submit details of their prescribing on a monthly basis. A letter from the Pharmaceutical Regulatory Unit has been sent to all applicable generally authorised prescribers notifying them of this change.

Page Updated: Thursday 1 November 2018
Contact page owner: Pharmaceutical Services